UNASSIGNED:通过全面评估来估计心力衰竭(HF)的经济负担对于将来改善治疗计划至关重要。这种估计也有助于对较新的HF治疗的报销决定。本研究旨在从卫生部的角度评估马来西亚HF治疗的费用。
未经评估:基于患病率的,在马来西亚的三家三级医院进行了自下而上的成本分析研究。在2016年1月1日至2018年12月31日期间接受治疗的慢性HF患者被纳入研究。HF的直接成本是根据从患者病历中提取的整个一年随访期间的患者医疗保健资源利用率估算的。总费用包括门诊费,住院治疗,药物,实验室测试和程序成本,根据射血分数(EF)和纽约心脏协会(NYHA)功能分类进行分类。
UNASSIGNED:本研究共纳入329例患者。每位HF患者每年的总费用(PPPY)的平均值±标准偏差为1,971±1,255美元,其中住院费用占总费用的74.7%。药物费用(42.0%)和手术费用(40.8%)占门诊和住院费用的最大比例。EF保留的HF患者的PPPY平均总成本最高,在2,410美元±1,226美元。NYHAII级的平均PPPY成本为2,044美元±1,528美元,是所有功能类别中最高的。患有基础冠状动脉疾病的患者平均总费用最高,与其他合并症相比,价格为2,438美元±1,456美元。与不使用血管紧张素受体脑啡肽抑制剂(ARNi)的患者相比,接受血管紧张素受体脑啡肽抑制剂(ARNi)的HF患者的HFPPPY总费用明显更高(2,439美元与1933美元,p<0.001)。住院治疗,经皮冠状动脉介入治疗,冠状动脉造影,合并症是HF的成本预测因子。
未经评估:住院费用是HF医疗费用的主要驱动因素。预防HF相关住院和改善HF管理的有效策略可能会降低马来西亚HF治疗的医疗保健成本。
UNASSIGNED: Estimation of the economic burden of heart failure (HF) through a complete evaluation is essential for improved treatment planning in the future. This estimation also helps in reimbursement decisions for newer HF treatments. This
study aims to estimate the cost of HF treatment in Malaysia from the Ministry of Health\'s perspective.
UNASSIGNED: A prevalence-based, bottom-up cost analysis
study was conducted in three tertiary hospitals in Malaysia. Chronic HF patients who received treatment between 1 January 2016 and 31 December 2018 were included in the
study. The direct cost of HF was estimated from the patients\' healthcare resource utilisation throughout a one-year follow-up period extracted from patients\' medical records. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests and procedure costs, categorised according to ejection fraction (EF) and the New York Heart Association (NYHA) functional classification.
UNASSIGNED: A total of 329 patients were included in the
study. The mean ± standard deviation of total cost per HF patient per-year (PPPY) was USD 1,971 ± USD 1,255, of which inpatient cost accounted for 74.7% of the total cost. Medication costs (42.0%) and procedure cost (40.8%) contributed to the largest proportion of outpatient and inpatient costs. HF patients with preserved EF had the highest mean total cost of PPPY, at USD 2,410 ± USD 1,226. The mean cost PPPY of NYHA class II was USD 2,044 ± USD 1,528, the highest among all the functional classes. Patients with underlying coronary artery disease had the highest mean total cost, at USD 2,438 ± USD 1,456, compared to other comorbidities. HF patients receiving angiotensin-receptor neprilysin-inhibitor (ARNi) had significantly higher total cost of HF PPPY in comparison to patients without ARNi consumption (USD 2,439 vs. USD 1,933, p < 0.001). Hospitalisation, percutaneous coronary intervention, coronary angiogram, and comorbidities were the cost predictors of HF.
UNASSIGNED: Inpatient cost was the main driver of healthcare cost for HF. Efficient strategies for preventing HF-related hospitalisation and improving HF management may potentially reduce the healthcare cost for HF treatment in Malaysia.